Decoding the Moment: New Rules for Vaccine Approvals
A Conversation with Alison Buttenheim, PhD, MBA, Paul Offit, MD, and Dan Gorenstein, presented by Penn LDI and Tradeoffs
The Trump administration’s sweeping efforts to reshape federal health policy have created a fast-moving, uncertain landscape for the health care sector and policymakers. In response, Penn LDI and Tradeoffs are launching the virtual event series, Decoding the Moment, to provide timely, evidence-based discussions on key federal policy changes.
Through conversations with leading experts, this series will explore the implications of recent actions and what they signal for the future.
Decoding the Moment kicks off with a virtual seminar on Friday, May 16 focused on the changes to the vaccine approval processes that were announced this week by the Trump administration requiring that all “new” vaccines be tested against a placebo, which HHS described as a “radical departure from past practices.” Public health experts say the change raises timing, ethics, and cost issues and could affect this year’s COVID-19 vaccine updates.
Join the conversation, featuring Paul Offit, MD and Alison Buttenheim, PhD, MBA, moderated by Tradeoffs’ Dan Gorenstein. The discussion will tackle what is proposed and why, what it could mean for vaccine availability, public confidence, and disease spread.
Speakers
Alison Buttenheim, PhD, MBA
Professor, Family and Community Health, Penn Nursing; Professor, Medical Ethics and Health Policy, Perelman School of Medicine; Scientific Director, Center for Health Incentives and Behavioral Economics (CHIBE), University of Pennsylvania
Paul A. Offit, MD
Director, Vaccine Education Center and Attending Physician, Division of Infectious Diseases, Children’s Hospital of Philadelphia
